Bloodwise | September 2018 |Over half of Brits don’t know symptoms of blood cancer
September is Blood Cancer Awareness Month and to raise awareness of blood cancers Bloodwise commissioned a survey to assess the general population’s understanding and knowledge of these types of cancer. Despite blood cancer being one of the most commonly diagnosed cancers, Bloodwise’s poll of 1000 adults found that only a tenth of the public were able to recognise its symptoms. Less than 1 % of people are “very confident” they could identify common symptoms of blood cancer, with over 50 per cent of the population not knowing any symptoms at all.
Blood cancer symptoms can be varied and often very vague. People can have just one or many of these before diagnosis – and in some cases, none at all:
- Persistent and unexplained tiredness
- Unexplained weight loss
- Unexplained bruising and/or bleeding
- Persistent infection
- Drenching night sweats
- Lumps or swellings in the neck, head, groin or stomach
- Bone/joint pain
Read the full article here
NHS England | August 2018 |Breast cancer survivors control their follow-up care in Maidstone
A new case study from NHS England highlights how patients with breast cancer in are able to control their own care in Maidstone, Kent. The Open Access programme enables patients to have access to regular mammograms, support advice and appropriate clinical follow up up to five years following treatment for breast cancer. The programme recognises patients as individuals and that the way in which they want to be supported may change during their recovery, the team introduced an Open Access Programme, based upon a successful model in place at the Royal Marsden Hospital.
- A reduction of 3,000 breast outpatient appointments
- Patients access suitable clinical appointments and contact their nurse appropriately.
- Timely referral to an appropriate clinician (ie surgeon, oncologist, nurse)
- Appointments aligned to patient need or want
- Fast access to the Cancer Nurse to answer questions and concerns.
Full story at NHS England
ICR | August 2018 | Drug combination gives ‘exciting’ results in ovarian and lung cancer in early trial
The results of an early clinical trial suggest that a combination of chemotherapy and a new drug could be used to provide treatment for patients with advanced ovarian and lung cancer, where other treatments had failed.
Scientists from The Institute of Cancer Research, London (ICR), and The Royal Marsden NHS Foundation Trust, decided to test vistusertib, which inhibits the activation of a specific molecule in ovarian cancer cells, to determine if the drug combination was safe for patients, the dosage and its efficacy. The combination of targeted drug vistusertib along with paclitaxel chemotherapy caused tumours of over 50 per cent of patients with ovarian cancer and over 33 % with lung cancer to shrink, and stopped patients’ cancers from growing for almost six months.
This far exceeds what is expected with standard treatments in patients with advanced disease who have already had, and have now become resistant to, standard treatment (Source: ICR).
Read the full news release from The Institute for Cancer Research Drug combination gives ‘exciting’ results in ovarian and lung cancer in early trial
In the news:
BBC News Drug cocktail can ‘shrink cancer tumours’
The Times Cancer drug Vistusertib gives hope for terminal patients
NHS England |August 2018 |NHS70: spotlight on cancer
More people are surviving cancer than ever before. As we continue to celebrate 70 years of the NHS, we shine the spotlight on some of the key milestones that improved cancer diagnosis, treatment and care over the decades, as well as looking to the future on NHS cancer care.
NHS England will also explore some of the work of the National Cancer Programme, as the NHS implements an ambitious. They have produced a timeline of cancer care improvements in cancer prevention, treatment and care (Source: NHS England).
You can watch the video here:
The NHS has played a major role in advancing cancer treatment and care locally, nationally and globally. In this video, we acknowledge some of the key milestones that marked huge improvements in cancer prevention, treatment and care.
Full details are available from NHS England
Public Health England | August 2018 | New data links route to cancer diagnosis and treatment
Public Health England (PHE) have released new data which illustrates how the way that cancer patients are diagnosed may affect their treatment options.
The national data links individual patients’ route to diagnosis, including screening, GP referrals, and emergency presentations, with the treatment patients go on to receive.
Those diagnosed through screening were likely to have the most treatment options available and receive treatments aimed at curing the cancer, in particular surgery to completely remove the tumour. This strongly supports the benefits of screening as a way of diagnosing cancer early, which evidence suggests leads to better patient outcomes, ultimately saving lives (Source: PHE).
Full news story at PHE
Health Quality Improvement Programme | August 2018| National Bowel Cancer Audit: The feasibility of reporting patient outcome measures as part of of a national colorectal cancer audit
Health Quality Improvement Programme (HQIP) has published the National Bowel Cancer Audit: The feasibility of reporting patient outcome measures
NHS England’s National Cancer PROMs Programme of the National Survivorship Initiative2 collected Patient Reported Outcome Measures (PROMs) for colorectal cancer patients in a one-off study in 2013. Patients were between one- and three-years from diagnosis at the point of being surveyed.
The aim of this study was to link the Patient Reported Outcome Measures (PROMs) for colorectal cancer patients in a one-off study in 2013, survey data to the National Bowel Cancer Audit (NBOCA) data to establish the feasibility of reporting PROMs as part of a national clinical audit. This was assessed according to i) the characteristics of responders compared to all eligible patients ii) the representativeness of the responders at different points along their pathway from diagnosis, iii) hospital trust variation in response rate, and iv) the validity of the measures in comparison to NBOCA measures (Source: HQIP).
The full report is available from HQIP here
Quality Health & National Cancer Patient Experience Advisory Group | July 2018 | National Cancer Patient Experience Survey 2017
The results of its national cancer patient experience survey have recently been published. Commissioned and managed by NHS England, the survey provides information to drive local quality improvements; monitors national progress on cancer care; assists commissioners and providers of cancer care; and helps to inform the
work of the various charities and stakeholder groups supporting patients with cancer.
The experience of cancer patients in England continues to be generally very positive. Asked to rate their care on a scale of zero (very poor) to 10 (very good), respondents gave an average rating of 8.8. On nearly half of the questions in the survey, over 80% of respondents gave positive responses.
•79% of respondents said that they were definitely involved as much as they wanted to be in decisions about their care and treatment
•91% of respondents said that they were given the name of a Clinical Nurse Specialist who would support them through their treatment
•86% of respondents said that it had been ‘quite easy’ or ‘very easy’ to contact their Clinical Nurse Specialist
•89% of respondents said that, overall, they were always treated with respect and dignity while they were in hospital
•94% of respondents said that hospital staff told them who to contact if they were worried about their condition or treatment after they left hospital
•60% of respondents said that they thought the GPs and nurses at their general practice definitely did everything they could to support them while they were having cancer treatment. (Source: Quality Health)